# Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

> **NCT03792841** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 212 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** acapatamab
- **DRUG:** Pembrolizumab
- **DRUG:** Etanercept
- **DRUG:** Cytochrome P450 (CYP) Cocktail

## Key facts

- **NCT ID:** NCT03792841
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-05
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 212 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792841, "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03792841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*